NCT03203837 is a clinical trial of Plasma collection in Hepatocellular Carcinoma, sponsored by Northwestern University.

Who is sponsoring NCT03203837?

NCT03203837 is sponsored by Northwestern University.

What drugs are being tested in NCT03203837?

Interventions in NCT03203837: Plasma collection.

What condition does NCT03203837 study?

NCT03203837 studies Hepatocellular Carcinoma.

Is NCT03203837 still recruiting?

NCT03203837 is currently terminated. Last updated 9 September 2020.

Last reviewed 2020-09-09 · How we verify

NCT03203837

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

Terminated Last updated 9 September 2020

What this trial tests

trial testing Plasma collection in Hepatocellular Carcinoma in 4 participants. Terminated before completion.

Timeline

5 July 2017

Primary endpoint
6 January 2020

6 January 2020

Quick facts

Lead sponsor	Northwestern University
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	4
Start date	5 July 2017
Primary completion	6 January 2020
Estimated completion	6 January 2020
Sites	1 location across United States

Drugs / interventions tested

Plasma collection — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →

Sponsor

Northwestern University

Who can join

18 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To analyze specific angiogenic, inflammatory and immune profiles in hepatocellular carcinoma patients who undergo radioembolization.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside.
Siracusano G, Tagliamonte M, Buonaguro L, Lopalco L. · · 2020 · cited 8× · PMID 31991677 · DOI 10.3390/vaccines8010041

Verify or expand the search:

Other trials of Plasma collection

Trials testing the same drug.

NCT05782400 — Multiomics Approach in Metastatic Clear Renal Cell Carcnoma · active not recruiting

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other Northwestern University trials

Trials by the same sponsor.

NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03203837 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Northwestern University
Last refreshed: 9 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03203837.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing